Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers

Next Previous
Trial Profile

A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimurutamab (Primary) ; Dexamethasone; Diphenhydramine; Ondansetron; Paracetamol
  • Indications Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Shanghai Henlius Biotech

Most Recent Events

  • 13 Mar 2021 Results published in the Investigational New Drugs
  • 28 Jul 2019 Status changed from recruiting to completed.
  • 11 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top